SpePharma launhces Xerotin and MuGard in Europe

SpePharm, a Dutch specialty pharmaceutical company, has launched two new drug products in Europe - MuGard and Xerotin - both aimed at  relieving some of the most debilitating side effects experienced by  cancer patients. The roll-out starts this month with Germany, Italy, the  UK, Nordic countries and Greece. The rest of Europe will follow over the  next 12 to 18 months. MuGard is a ready-to-use, muco-adhesive oral rinse  for the prevention and management of the lesions and symptoms of oral  mucositis, a condition mainly caused or induced by radiation and/or  chemotherapy. Xerotin is a ready-to-use mouth moisturizing spray  indicated for the relief of xerostomia, the reduced level of saliva  that is a common side effect of some cancer treatments especially  radiotherapy for head and neck cancer, Sjogren's syndrome, nerve damage  and also a common side effect of chronic administration of many  medications.